How should a 2‑month‑old infant with viral hepatitis, markedly elevated transaminases, normal bilirubin, normal coagulation profile, normal albumin, normal glucose, normal abdominal ultrasound, neutropenia with reactive lymphocytosis, and who has been receiving ampicillin, cefotaxime, and acyclovir for four days be managed given persistent transaminase elevation and worsening neutropenia without any clinical symptoms?

Management of Asymptomatic 2-Month-Old with Viral Hepatitis, Elevated Transaminases, and Neutropenia

Stop all antibiotics immediately and transition to close clinical observation with serial monitoring, as this infant has no clinical signs of bacterial infection and the current antimicrobial regimen may be contributing to worsening neutropenia.

Immediate Actions

Discontinue ampicillin, cefotaxim, and acyclovir. The infant is afebrile, clinically well, has normal synthetic liver function (normal coagulation, albumin, bilirubin), and shows no evidence of bacterial sepsis or herpes simplex virus infection requiring treatment. The worsening neutropenia after 4 days of broad-spectrum antibiotics strongly suggests drug-induced bone marrow suppression 1, 2. Both cefotaxime and ampicillin can cause leukopenia, neutropenia, and granulocytopenia, particularly with prolonged courses exceeding 10 days, though hematologic toxicity can occur earlier 1, 2.

The clinical picture—neutropenia with reactive lymphocytosis following sibling URTI contact—is classic for viral hepatitis in infancy, not bacterial infection or HSV hepatitis. Acyclovir was empirically started but lacks indication in an afebrile, well-appearing infant without mucocutaneous lesions, encephalitis, or disseminated disease.

Diagnostic Workup

Obtain specific viral serologies and PCR testing:

• Hepatitis A IgM (most common cause of acute viral hepatitis in children) 3, 4
• Hepatitis E IgM (second most common, can coinfect with HAV) 3, 5
• CMV PCR in urine and blood (postnatally acquired CMV can cause prolonged transaminase elevation and neutropenia in young infants, even with indirect hyperbilirubinemia) 6
• Adenovirus PCR from nasopharyngeal swab and blood (emerging cause of severe hepatitis in infants) 7, 8
• EBV PCR (less common at 2 months but possible)
• Enterovirus PCR (can cause hepatitis in young infants)

The normal bilirubin is reassuring but does not exclude viral hepatitis—many infants with viral hepatitis have elevated transaminases with minimal or no hyperbilirubinemia 9, 3. The reactive lymphocytosis with neutropenia is characteristic of viral infection, not bacterial sepsis.

Monitoring Strategy

Serial laboratory monitoring every 2-3 days initially:

• Complete blood count with differential to track neutropenia recovery (should improve within 7-10 days after stopping antibiotics if drug-induced)
• AST, ALT (expect gradual decline over weeks; persistent elevation is common in viral hepatitis even as clinical symptoms resolve) 10
• PT/INR, albumin (to detect any progression to synthetic dysfunction)
• Total and direct bilirubin (to monitor for cholestatic evolution)

Clinical monitoring:

• Feeding tolerance, weight gain, activity level
• Hepatomegaly progression or regression
• Any new bleeding manifestations (gum bleeding, petechiae, bruising)
• Fever or other signs of secondary bacterial infection while neutropenic

Expected Clinical Course

Most viral hepatitis in infants follows a benign, self-limited course. Transaminases may remain elevated for weeks to months despite clinical recovery 10, 9. The normal coagulation profile, albumin, and bilirubin indicate preserved synthetic function and low risk of acute liver failure. Hepatitis A, the most common cause, typically resolves spontaneously with supportive care in children 3, 4.

Neutropenia management: If absolute neutrophil count (ANC) is >500/μL, no specific intervention is needed beyond monitoring. If ANC <500/μL, consider temporary isolation from sick contacts and maintain high index of suspicion for secondary bacterial infection, though this infant currently shows no signs of infection.

When to Escalate Care

Immediate pediatric hepatology referral if:

• PT/INR becomes prolonged (>1.5) or fails to correct with vitamin K
• Albumin drops below 3.0 g/dL
• Total bilirubin rises above 5 mg/dL or direct bilirubin becomes elevated
• Clinical deterioration (lethargy, poor feeding, vomiting, altered mental status)
• Transaminases continue rising or exceed 10x upper limit of normal
• Development of ascites, edema, or hepatosplenomegaly

Consider liver biopsy only if: Transaminases remain significantly elevated (>5x ULN) beyond 8-12 weeks without identified viral etiology, or if there is concern for metabolic disease, autoimmune hepatitis, or alpha-1 antitrypsin deficiency 10, 11.

Pitfalls to Avoid

Do not continue empiric antibiotics without clear bacterial infection. The reflexive use of broad-spectrum antibiotics in infants with elevated transaminases and neutropenia often represents diagnostic uncertainty rather than true indication. This approach causes harm through drug toxicity (worsening neutropenia, potential hepatotoxicity) and delays recognition of the true viral etiology 1, 2.

Do not treat chronic hepatitis B if identified. If HBsAg testing reveals chronic HBV infection (unlikely given acute presentation), treatment is not indicated in a 2-month-old infant. Infants are typically in the immune-tolerant phase with high viral loads but minimal inflammation, and treatment carries high risk of resistance with no established benefit 12.

Do not overlook postnatally acquired CMV. This diagnosis is frequently missed because clinicians associate CMV with congenital infection. Postnatal CMV (typically from breast milk) can cause prolonged transaminase elevation, neutropenia, and even isolated indirect hyperbilirubinemia in young infants, yet usually follows a benign course requiring only observation 6.